Get the latest Science News and Discoveries

Novel dual-target IL-17A/F monoclonal antibody XKH004 shows 52-week efficacy and safety in active ankylosing spondylitis in phase 3 trial

None

Related news:

Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC

Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Phase 1 Study Supports Recommended Phase 3 Dose for Investigational EGFR x HER3 Antibody-Drug Conjugate in EGFR-Mutated Lung Cancer